GlobeNewswire by notified

Clariant AG: Record 2022 sales growth, EBITDA and cash conversion driven by strong operating performance; dividend increase proposed



  • Q42022:Sales grew by 12% in local currency to CHF 1.323 billion,underpinned by strong pricing in a softening demand environment,
    EBITDA margin was 11.6% (14.7 % excluding CHF 40 million restructuring charges related to the implementation of the new operating model)
  • FY 2022:Sales increased by 24% in local currency to CHF 5.198 billion,
    EBITDA margin was 15.6 % (16.4 %excluding CHF 40 million restructuring charges in
    Q4 2022 related to the implementation of the new operating model)
  • FY 2022: Net result for total Group at CHF 116 million
  • FY 2022: Net operating cash flow increased by 38% to CHF 502 million,
    CHF 293 million free cash flow resulting in a 36% free cash flow conversion
  • FY 2022: Increased distribution of CHF 0.42 per share proposed to AGM on 4 April 2023
  • Outlook2023: Full yearsales around CHF 5billion with the aim to slightly improvethe year-on-year reported Group EBITDA margin levelin a challenging macro environment,which is expected to improve in H2 2023

“In the fourth quarter of 2022, pricing continued to have a significant positive impact on sales growth and EBITDA margin, despite softer end markets in some businesses. The hard work of all our colleagues enabled us to successfully increase year-on-year sales in all regions, including China,” said Conrad Keijzer, Chief Executive Officer of Clariant. “I am particularly proud of our continued strong operating performance and that our full year 16.4 % EBITDA margin (excluding restructuring charges of CHF 40 million related to the implementation of the new operating model) slightly exceeded the full year 2022 guidance we previously communicated. Our shareholders will participate in our strong operational performance with an increased distribution of CHF 0.42 per share. From a sustainability perspective, the magnitude of Clariant’s Scope 1 and 2 total greenhouse gas emission improvement in 2022 is positive proof that we have managed to decouple emissions from our 7 % volume growth.”

“In the full year 2022, we achieved above-market sales growth and a margin improvement in a challenging inflationary environment. We have set the company up for growth in the years ahead with the measures undertaken during the implementation of our new operating model. The benefits of our new model include better customer orientation, better and faster decision making, greater empowerment, more accountability, and improved transparency which will enable Clariant to achieve its 2025 targets,” Conrad Keijzer added.

Key Financial Group Figures

Continuing operations Fourth Quarter     Full Year
in CHF million 20222021% CHF% LC20222021% CHF% LC
Sales 1 323 1 242 7 12 5 198 4 372 19 24
EBITDA 154 203 -24 810 708 14
- margin 11.6 % 16.3 % 15.6 % 16.2 %
EBITDA before exceptional items203230-1289376018
- margin15.3 %18.5 %17.2 %17.4 %
EBIT 72 440
Return on invested capital (ROIC) 1.5%(2) 9.9 %
Net result from continuing operations -101 292
Net result total (1)116 373
Net operating cash flow (1) 502 363
Number of employees (1) 11 148(4) 13 374(5)
Discontinued operations (3)
Sales 0 240 n.m. n.m. 0 912 n.m. n.m.
Net result from discontinued operations 217 81

(1) Total Group, including discontinued operations
(2) Excl. impairment charges of CHF 453 million for the North American Land Oil divestment and the Podari plant; the ROIC was 10.6 %
(3) Pigments divested on 3 January 2022
(4) As of 31 December 2022
(5) As of 31 December 2021

Fourth Quarter 2022Continuedsales growth withprofitability impacted by restructuring charges


Clariant, a focused, sustainable, and innovative specialty chemical company, today announced its fourth quarter and full year 2022 results. In the fourth quarter of 2022, continuing operations sales were CHF 1.323 billion, compared to CHF 1.242 billion in the fourth quarter of 2021. This corresponds to an increase of 12 % in local currency and 7 % in Swiss francs. Pricing positively impacted the Group sales result by 13 % while volumes declined by 1 %, with a currency impact of - 5 %. The strong sales growth in Catalysis and Natural Resources outpaced the anticipated muted development in Care Chemicals.

In the fourth quarter of 2022, sales grew solidly in all geographic regions. European sales grew by 6 % in local currency, as prices increased while volume growth slowed. Sales in Asia-Pacific also grew by 15 %, primarily propelled by China with 14 % sales growth. North American sales were 16 % higher, and Latin American sales grew 18 %. The robust advances in both regions were supported by volume growth in Catalysis and strong pricing in Natural Resources. The Middle East & Africa increased sales by 9 %.

In the fourth quarter of 2022, Care Chemicals increased sales by 4 % in local currency by maintaining pricing while volumes declined as expected. This progress was driven by double-digit growth in Consumer Care – Crop Solutions and Personal Care in particular – while Industrial Applications sales slowed slightly. Catalysis sales rose by 18 % in local currency, mainly driven by volume growth and primarily due to growth in Petrochemicals and Syngas. Natural Resources sales increased by 16 % in local currency due to increased pricing with growth attributable to all three Business Units, especially Oil and Mining Services.

The absolute continuing operations EBITDA decreased by 24 % to CHF 154 million, and the corresponding 11.6 % margin was negatively impacted by restructuring expenses of CHF 40 million for the implementation of the new operating model. Excluding this one-time charge, the 14.7 % EBITDA margin was below the 16.3 % reported in the fourth quarter of the previous year, driven by a negative CHF 20 million EBITDA impact from project cost and higher operational cost for the sunliquid® production plant in Romania and the expected lower volumes in Care Chemicals and Additives.

Full Year 2022 – ESG Update – Leading in sustainability

In the full year 2022, the Group’s Scope 1 and 2 total greenhouse gas emissions for continuing operations improved to 0.62 metric tons from 0.71 metric tons in 2021, a decline of 13 % compared to prior year. The total indirect greenhouse gas emissions for purchased goods and services (Scope 3) also decreased by 4 % to 2.58 metric tons from 2.70 metric tons in 2021.

These improvements were the result of increased energy efficiency measures at operating sites, an accelerated transition to renewables in our operations, as well as a higher share of green electricity purchased. For example, in Bonthapally, India, the replacement of coal with biomass derived from agricultural waste enables annual savings of 10 000 tons of CO2 emissions. At Clariant’s sites in Indonesia, a ten-year purchase power agreement (PPA) has been in place since 2021, covering most of the electricity demand across all business units with a reduction of 21 000 tons of greenhouse gas emissions in 2022. These results and initiatives are positive proof that Clariant has been able to decouple its emissions from its increasing volume sales (+ 7 %) and demonstrate significant progress towards the Group’s emissions reduction targets.

The Group also marked a milestone in its continuous efforts to increase transparency for customers into greenhouse gas emissions associated with a product throughout its lifecycle. With the launch of its product carbon footprint (PCF) tool, ‘CliMate,’ Clariant offers selected product carbon footprint calculations across its portfolio, in line with the ISO 14067 standard.

Another highlight in 2022 was Clariant’s low-carbon, high-performing solutions that create value for customers. Clariant’s solution contributes to the catalytic abatement of nitrous oxide (N2O) emitted during the production of nitric acid, which is a valuable base chemical primarily used in fertilizers. Through its global climate campaign, the Group enables ten nitric acid producers to reduce more than 4 million metric tons of CO2 emissions annually. Clariant received the 2022 Sustainability Leadership Award from the American Chemistry Council for this achievement.

Full Year 2022Teamwork, pricing, and cost disciplineunderpinned higher sales,while restructuringcharges impacted EBITDA

In the full year 2022, sales from continuing operations were CHF 5.198 billion, compared to CHF 4.372 billion in the full year 2021. This corresponds to an increase of 24 % in local currency and 19 % in Swiss francs. Both pricing and volume growth had a positive impact on the Group of 17 % and 7 %, respectively, while the currency impact was – 5 %.

In the full year 2022, sales growth exceeded 20 % in local currency in all geographic regions. Clariant’s performance was especially strong in North America, Latin America, and the Middle East & Africa.

Care Chemicals grew sales by 28 % in local currency in full year 2022 with double-digit sales growth in all key businesses. In Catalysis, the top line was up by 14 % in local currency, propelled by the Petrochemicals and Specialty Catalysts businesses. Oil and Mining Services, Functional Minerals, and Additives in particular, all contributed to the 25 % local currency sales growth reported at Natural Resources.

The continuing operations EBITDA increased by 14 % to CHF 810 million as the Group improved profitability on the back of sales growth. The EBITDA margin was 15.6 %, versus 16.2 % in the previous year. Adjusting for restructuring expenses of CHF 40 million related to the implementation of the new operating model booked in the fourth quarter of 2022, the 16.4 % EBITDA margin exceeded the previous year’s level. The adjusted profitability improvement was propelled by pricing measures that more than fully offset the high raw material cost increase (25 % year-on-year) and higher energy (+ 35 %) and logistics cost (+ 6 %). The Group’s ongoing cost discipline and the profitability improvement in Care Chemicals and Natural Resources more than offset the relative weakness in Catalysis, which includes a CHF 43 million negative impact from sunliquid®.

The EBIT decreased to CHF 72 million in the full year 2022 from CHF 440 million in the previous year, mainly due to three impairments totaling CHF 462 million. A non-cash impairment in the amount of CHF 233 million was related to the sale of Clariant’s North American Land Oil business to Dorf Ketal, which is expected to close in the first quarter of 2023. A further impairment of CHF 220 million was booked for the sunliquid® bioethanol plant in Romania based on the delayed ramp up and the plant’s current financial performance. A CHF 5 million impairment was also made on Clariant’s assets in Ukraine. Excluding these charges, the EBIT increased to CHF 534 million, 21 % above the full year 2021.

In the full year 2022, the total Group net result was CHF 116 million, versus CHF 373 million in the previous year. The net result was lifted by the net result from discontinued operations of CHF 217 million, mainly related to the gain on the Pigments disposal; the strong business performance of the continuing operations; and the corresponding margin improvement, while impairments had a negative impact of CHF 462 million.

Net operating cash flow for the total Group increased to CHF 502 million from CHF 363 million in the full year 2021. This development was mainly attributable to strong underlying earnings and net working capital management. The increased free cash flow of CHF 293 million compared to CHF 6 million in 2021 resulted in a conversion rate in 2022 of 36 %, versus 1 % a year ago and is attributable to the strong operating cash flow and disciplined capital expenditures.

Net debt for the total Group decreased to CHF 750 million, versus CHF 1.535 billion recorded at the end of 2021. This development is largely attributable to a significant reduction in current financial debt and an increase in short-term deposits due to proceeds received from the divestment of the Pigments business and the Scientific Design Company stake.

The Board of Directors recommends an increased regular distribution of CHF 0.42 per share to the Annual General Meeting (AGM) on 4 April 2023 based on the strong performance in 2022. This distribution is proposed to be made through a capital reduction by way of a par value reduction.

Outlook – Full Year 2023

Clariant aims to grow above the market to achieve higher profitability through sustainability and innovation. Clariant has become a true specialty chemical company and confirms its 2025 ambition to deliver profitable sales growth (4 – 6 % CAGR), a Group EBITDA margin between 19 – 21 %, and a free cash flow conversion of around 40 %.

As of 1 January 2023, Clariant will report in the Business Unit structure aligned with its new operating model. The Business Unit Care Chemicals includes the former Business Area Care Chemicals and the Business Unit Oil & Mining Services (previously part of the former Business Area Natural Resources). The Business Unit Catalysts is unchanged from the former Business Area Catalysis. The Business Unit Adsorbents & Additives is a combination of the former Business Units Functional Minerals and Additives (both previously part of the former Business Area Natural Resources).

From a macroeconomic perspective, Clariant anticipates a soft recessionary environment in the first half of 2023, compared to a very strong first half of 2022, and expects to see an economic recovery in the second half of 2023 while uncertainties and risks related to the economic environment remain. For the full year 2023, Clariant expects to achieve sales of around CHF 5 billion, including a net negative top line impact of around CHF 130 million from divestments and the bolt-on acquisition. Clariant aims to slightly improve its year-on-year reported EBITDA margin due to a continued recovery in Catalysts, which is expected to offset lower sales volumes in the other Business Units. Clariant expects an increasing negative annualized sunliquid® impact and a continued inflationary environment given the current economic outlook, counterbalanced by savings benefits from the restructuring programs.

Q4/FY 2022 Media Release
FY 2022 Financial Review


Jochen Dubiel
Phone +41 61 469 63 63

Anne Maier
Phone +41 61 469 63 63

Ellese Caruana
Phone +41 61 469 63 63


Andreas Schwarzwälder
Phone +41 61 469 63 73

Maria Ivek
Phone +41 61 469 63 73

Thijs Bouwens
Phone +41 61 469 63 73

Follow us on Twitter, Facebook, LinkedIn, Instagram.

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

Clariant is a focused, sustainable, and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2022, Clariant totaled a staff number of 11 148 and recorded sales of CHF 5.198 billion in the fiscal year for its continuing businesses. The company reports in three Business Areas: Care Chemicals, Catalysis, and Natural Resources. As of January 2023, the Group conducts its business through the three newly formed Business Units Care Chemicals, Catalysts, and Adsorbents & Additives and will report accordingly as of the first quarter of 2023. Clariant’s corporate strategy is led by the overarching purpose of ‘Greater chemistry – between people and planet,’ and reflects the importance of connecting customer focus, innovation, sustainability, and people.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CFO Martin Klöti to leave Schweiter Technologies29.3.2023 06:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR CFO Martin Klöti to leave Schweiter Technologies Martin Klöti, Chief Financial Officer (CFO) and member of the Management of Schweiter Technologies, has decided to leave the company Steinhausen, 29 March 2023 – Martin Klöti, who has been with Schweiter Technologies since 2003 and CFO of the Group since 2014, has decided to leave the Management as of September 2023 to take up a new position outside the company. The Board of Directors will be sorry to see him leave and wishes to take this opportunity to thank him for his many years of dedicated service and his enormous contribution to the development of Schweiter Technologies. The search for his successor will be initiated forthwith. For further information please contact: Martin Klöti, CFO Tel. +41 41 757 77 00 ABOUT SCHWEITER Schweiter Technologies, with its head office in Steinhausen, Switzerland, is a globally active Group focusing on composites solutions with its divi

Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia29.3.2023 05:39:38 CEST | Press release

-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the development, medical affairs, production of finished products, and commercialization of toripalimab within the cooperation territory. The profits available for distribution by Excellmab will be distributed in proportion to the respective shareholdings of the parties -- Using the Excellmab platform, the two parties also plan to collaborate extensively to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development -- According to the progress of toripalimab’s R&D and other projects, Junshi Biosciences may receive a milestone payment of up to approximately US$4.52 million, plus a certain percentage of royalties on net sales SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Bioscience

Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release

SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor

Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release

Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at The minutes of the Annual General Meeting will also be pub